214 related articles for article (PubMed ID: 33846541)
41. ABT-199 shows effectiveness in CLL.
Cancer Discov; 2014 Sep; 4(9):OF7. PubMed ID: 25185206
[TBL] [Abstract][Full Text] [Related]
42. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
43. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
Hammond D; Montalban-Bravo G
Curr Hematol Malig Rep; 2021 Oct; 16(5):405-417. PubMed ID: 34499330
[TBL] [Abstract][Full Text] [Related]
44. Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Hengeveld PJ; Schilperoord-Vermeulen J; van der Klift MY; Dubois JMN; Kolijn PM; Kavelaars FG; Rijken M; Dobber JA; Nasserinejad K; Kersting S; Westerweel PE; Kater AP; Langerak AW; Levin MD
Blood Cancer J; 2023 Jul; 13(1):102. PubMed ID: 37400508
[No Abstract] [Full Text] [Related]
45. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
46. Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
Garcia-Horton A; Maze D; McNamara CJ; Sibai H; Gupta V; Murphy T
Leuk Lymphoma; 2021 Jun; 62(6):1525-1527. PubMed ID: 33448888
[No Abstract] [Full Text] [Related]
47. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
[TBL] [Abstract][Full Text] [Related]
48. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.
Komrokji RS; Singh AM; Ali NA; Chan O; Padron E; Sweet K; Kuykendall A; Lancet JE; Sallman DA
Blood Cancer J; 2022 Nov; 12(11):148. PubMed ID: 36329025
[No Abstract] [Full Text] [Related]
49. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP;
Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675
[TBL] [Abstract][Full Text] [Related]
50. Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases.
Saburi M; Nishikawa T; Miyazaki Y; Kohno K; Sakata M; Okuhiro K; Nakayama T; Ohtsuka E; Ogata M
J Clin Exp Hematop; 2024; 64(2):152-155. PubMed ID: 38925975
[No Abstract] [Full Text] [Related]
51. Autoimmune hemolytic anemia, adverse event to venetoclax.
Carriles C; Ordóñez-Fernández L; Arias-Martínez A; Menárguez-Blanc R; Rosado-María MC
Farm Hosp; 2019 Sep; 43(5):166-167. PubMed ID: 31469630
[No Abstract] [Full Text] [Related]
52. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Gopalakrishnan S; Wierda W; Chyla B; Menon R; Miles D; Humerickhouse R; Awni W; Salem AH; Mensing S; Freise KJ
Clin Pharmacol Ther; 2021 Feb; 109(2):424-432. PubMed ID: 32749675
[TBL] [Abstract][Full Text] [Related]
53. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
54. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
55. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
Herling CD; Abedpour N; Weiss J; Schmitt A; Jachimowicz RD; Merkel O; Cartolano M; Oberbeck S; Mayer P; Berg V; Thomalla D; Kutsch N; Stiefelhagen M; Cramer P; Wendtner CM; Persigehl T; Saleh A; Altmüller J; Nürnberg P; Pallasch C; Achter V; Lang U; Eichhorst B; Castiglione R; Schäfer SC; Büttner R; Kreuzer KA; Reinhardt HC; Hallek M; Frenzel LP; Peifer M
Nat Commun; 2018 Feb; 9(1):727. PubMed ID: 29463802
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Roberts AW; Ma S; Kipps TJ; Coutre SE; Davids MS; Eichhorst B; Hallek M; Byrd JC; Humphrey K; Zhou L; Chyla B; Nielsen J; Potluri J; Kim SY; Verdugo M; Stilgenbauer S; Wierda WG; Seymour JF
Blood; 2019 Jul; 134(2):111-122. PubMed ID: 31023700
[TBL] [Abstract][Full Text] [Related]
57. Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.
Robak E; Jesionek-Kupnicka D; Stelmach P; Kupnicki P; Szataniak M; Robak T
Ann Hematol; 2022 Jun; 101(6):1387-1392. PubMed ID: 35187604
[No Abstract] [Full Text] [Related]
58. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Thompson MC; Harrup RA; Coombs CC; Roeker LE; Pu JJ; Choi MY; Barr PM; Allan JN; Šimkovič M; Leslie L; Rhodes J; Chong EA; Kamdar M; Skarbnik A; Lansigan F; McCall B; Saja K; Dyer MJS; Walter HS; Lefebure M; Thadani-Mulero M; Boyer M; Biondo J; Sail K; Manzoor BS; Furman R; Bantilan KS; Goy A; Feldman T; Labella D; Schuster SJ; Park J; Palomba L; Zelenetz A; Eyre TA; Kater AP; Seymour JF; Mato AR
Blood Adv; 2022 Aug; 6(15):4553-4557. PubMed ID: 35736670
[No Abstract] [Full Text] [Related]
59. Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations.
Hecker JS; Pachzelt L; Götze KS
Expert Rev Hematol; 2021 Sep; 14(9):789-793. PubMed ID: 34405747
[No Abstract] [Full Text] [Related]
60. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
